Biological markers for longevity and diseases and uses thereof
AssigneeAlbert Einstein College of Medicine of Yeshiva University
InventorNir Barzilai
Life of this patent
Estimating the term…
Abstract
This invention provides methods of using of the sizes and levels of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles, the −641 allele of the promoter of the gene encoding apolipoprotein C-3 (APOC-3), the 405 allele of the gene encoding cholesteryl ester transfer protein (CETP), and plasma levels of insulin-like growth factor-1 (IGF-1), adiponectin, CETP and APOC-3, for determining and increasing an individual's likelihood of longevity and of retaining cognitive function during aging, and for determining and decreasing an individual's likelihood of developing a cardiovascular-, metabolic- or age-related disease.
Claims21
1-146. (canceled)
A method of determining a subject's likelihood of longevity, likelihood of developing a cardiovascular related disease, likelihood of developing a metabolic syndrome, or likelihood of retaining cognitive function during aging, the method comprising comparing high density lipoprotein (HDL) particle size from the subject's plasma with high density lipoprotein (HDL) particle size from a control population, wherein a larger size of the subject's high density lipoprotein (HDL) particles compared to the control population indicates that the subject has an increased likelihood of longevity, a decreased likelihood of developing a cardiovascular related disease, a decreased likelihood of developing a metabolic syndrome or an increased likelihood of retaining cognitive function during aging, or wherein a smaller size of the subject's high density lipoprotein (HDL) particles compared to the control population indicates that the subject has an increased likelihood of developing a cardiovascular related disease or an increased likelihood of developing a metabolic syndrome.
A method of determining a subject's likelihood of longevity or of developing a metabolic syndrome, the method comprising comparing low density lipoprotein (LDL) particle size from the subject's plasma with low density lipoprotein (LDL) particle size from a control population, wherein a larger size of the subject's low density lipoprotein (LDL) particles compared to the control population indicates that the subject has an increased likelihood of longevity or a decreased likelihood of developing a metabolic syndrome or wherein a smaller size of the subject's low density lipoprotein (LDL) particles compared to the control population indicates that the subject has an increased likelihood of developing a metabolic syndrome.
Dependencies are inferred from the claim text.